{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:31:49Z","timestamp":1787959909929,"version":"build-2784847793"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T00:00:00Z","timestamp":1694995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"},{"start":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T00:00:00Z","timestamp":1694995200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Although trials have proven the group-level effectiveness of various therapies for heart failure with reduced ejection fraction (HFrEF), important differences in absolute effectiveness exist between individuals. We developed and validated the LIFEtime-perspective for Heart Failure (LIFE-HF) model for the prediction of individual (lifetime) risk and treatment benefit in patients with HFrEF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Cox proportional hazards functions with age as the time scale were developed in the PARADIGM-HF and ATMOSPHERE trials (n\u2009=\u200915\u2009415). Outcomes were cardiovascular death, heart failure (HF) hospitalization or cardiovascular death, and non-cardiovascular mortality. Predictors were age, sex, New York Heart Association class, prior HF hospitalization, diabetes mellitus, extracardiac vascular disease, systolic blood pressure, left ventricular ejection fraction, N-terminal pro-B-type natriuretic peptide, and glomerular filtration rate. The functions were combined in life-tables to predict individual overall and HF hospitalization-free survival. External validation was performed in the SwedeHF registry, ASIAN-HF registry, and DAPA-HF trial (n\u2009=\u200951\u2009286). Calibration of 2- to 10-year risk was adequate, and c-statistics were 0.65\u20130.74. An interactive tool was developed combining the model with hazard ratios from trials to allow estimation of an individual's (lifetime) risk and treatment benefit in clinical practice. Applying the tool to the development cohort, combined treatment with a mineralocorticoid receptor antagonist, sodium\u2013glucose cotransporter 2 inhibitor, and angiotensin receptor\u2013neprilysin inhibitor was estimated to afford a median of 2.5 (interquartile range [IQR] 1.7\u20133.7) and 3.7 (IQR 2.4\u20135.5) additional years of overall and HF hospitalization-free survival, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The LIFE-HF model enables estimation of lifelong overall and HF hospitalization-free survival, and (lifetime) treatment benefit for individual patients with HFrEF. It could serve as a tool to improve the management of HFrEF by facilitating personalized medicine and shared decision-making.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.3028","type":"journal-article","created":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T23:45:29Z","timestamp":1694389529000},"page":"1962-1975","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Personalized Lifetime Prediction of Survival and Treatment Benefit in Patients with Heart Failure with Reduced Ejection Fraction: The LIFE-HF Model"],"prefix":"10.1093","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2579-900X","authenticated-orcid":false,"given":"Pascal M.","family":"Burger","sequence":"first","affiliation":[{"name":"Department of Vascular Medicine, University Medical Centre Utrecht , Utrecht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluigi","family":"Savarese","sequence":"additional","affiliation":[{"name":"Department of Medicine, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper","family":"Tromp","sequence":"additional","affiliation":[{"name":"Saw Swee Hock School of Public Health, National University of Singapore , Singapore ,","place":["Singapore"]},{"name":"National University Health System Singapore , Singapore ,","place":["Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carly","family":"Adamson","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep S.","family":"Jhund","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Benson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Hage","sequence":"additional","affiliation":[{"name":"Department of Medicine, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan Ting","family":"Tay","sequence":"additional","affiliation":[{"name":"National Heart Centre Singapore , Singapore ,","place":["Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milton","family":"Packer","sequence":"additional","affiliation":[{"name":"Baylor Heart and Vascular Institute, Baylor University Medical Centre , Dallas, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Rossello","sequence":"additional","affiliation":[{"name":"Centro Nacional de Investigaciones Cardiovasculares , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"McEvoy","sequence":"additional","affiliation":[{"name":"National Institute for Prevention and Cardiovascular Health, National University of Ireland Galway , Galway ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"De Bacquer","sequence":"additional","affiliation":[{"name":"Department of Public Health and Primary Care, Ghent University , Ghent ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Timmis","sequence":"additional","affiliation":[{"name":"William Harvey Research Institute, Queen Mary University of London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panos","family":"Vardas","sequence":"additional","affiliation":[{"name":"Heraklion University Hospital , Crete ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian M.","family":"Graham","sequence":"additional","affiliation":[{"name":"School of Medicine, Trinity College Dublin, The University of Dublin, College Green , Dublin ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Di Angelantonio","sequence":"additional","affiliation":[{"name":"Department of Public Health and Primary Care, University of Cambridge , Cambridge ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank L.J.","family":"Visseren","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, University Medical Centre Utrecht , Utrecht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.V.","family":"McMurray","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn S.P.","family":"Lam","sequence":"additional","affiliation":[{"name":"National Heart Centre Singapore , Singapore ,","place":["Singapore"]},{"name":"Duke-National University of Singapore , Singapore ,","place":["Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars H.","family":"Lund","sequence":"additional","affiliation":[{"name":"Department of Medicine, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Koudstaal","sequence":"additional","affiliation":[{"name":"Green Heart Hospital , Gouda ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jannick A.N.","family":"Dorresteijn","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, University Medical Centre Utrecht , Utrecht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arend","family":"Mosterd","sequence":"additional","affiliation":[{"name":"Meander Medical Centre , Amersfoort ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"in collaboration with the European Society of Cardiology's Cardiovascular Risk Collaboration (ESC CRC)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,9,18]]},"reference":[{"key":"2026010913114972000_ejhf3028-bib-0001","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/ejhf.1858","article-title":"Epidemiology of heart failure","volume":"22","author":"Groenewegen","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026010913114972000_ejhf3028-bib-0002","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026010913114972000_ejhf3028-bib-0003","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA Guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026010913114972000_ejhf3028-bib-0004","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: The CHAMP-HF registry","volume":"72","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026010913114972000_ejhf3028-bib-0005","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jchf.2018.10.010","article-title":"Contemporary drug treatment of chronic heart failure with reduced ejection fraction: The CHECK-HF registry","volume":"7","author":"Brunner-la Rocca","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2026010913114972000_ejhf3028-bib-0006","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.jchf.2023.04.017","article-title":"Mortality, outcomes, costs, and use of medicines following a first heart failure hospitalization: EVOLUTION HF","volume":"11","author":"Bozkurt","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026010913114972000_ejhf3028-bib-0007","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1001\/jama.2023.5942","article-title":"Global variations in heart failure etiology, management, and outcomes","volume":"329","author":"G-CHF Investigators","year":"2023","journal-title":"JAMA"},{"key":"2026010913114972000_ejhf3028-bib-0008","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(20)30748-0","article-title":"Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: A comparative analysis of three randomised controlled trials","volume":"396","author":"Vaduganathan","year":"2020","journal-title":"Lancet"},{"key":"2026010913114972000_ejhf3028-bib-0009","article-title":"Personalized evidence based medicine: Predictive approaches to heterogeneous treatment effects","volume":"363","author":"Kent","year":"2018","journal-title":"BMJ"},{"key":"2026010913114972000_ejhf3028-bib-0010","article-title":"How to translate clinical trial results into gain in healthy life expectancy for individual patients","volume":"352","author":"Dorresteijn","year":"2016","journal-title":"BMJ"},{"key":"2026010913114972000_ejhf3028-bib-0011","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jchf.2014.04.008","article-title":"Risk prediction in patients with heart failure: A systematic review and analysis","volume":"2","author":"Rahimi","year":"2014","journal-title":"JACC Heart Fail."},{"key":"2026010913114972000_ejhf3028-bib-0012","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jchf.2014.04.006","article-title":"Factors influencing the predictive power of models for predicting mortality and\/or heart failure hospitalization in patients with heart failure","volume":"2","author":"Ouwerkerk","year":"2014","journal-title":"JACC Heart Fail."},{"key":"2026010913114972000_ejhf3028-bib-0013","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jamacardio.2019.5850","article-title":"Prognostic models derived in PARADIGM-HF and validated in ATMOSPHERE and the Swedish Heart Failure Registry to predict mortality and morbidity in chronic heart failure","volume":"5","author":"Simpson","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2026010913114972000_ejhf3028-bib-0014","doi-asserted-by":"crossref","first-page":"4455","DOI":"10.1093\/eurheartj\/ehab579","article-title":"Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: The EMPEROR-Reduced trial","volume":"42","author":"Pocock","year":"2021","journal-title":"Eur Heart J"},{"key":"2026010913114972000_ejhf3028-bib-0015","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/ejhf.785","article-title":"Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure","volume":"19","author":"Voors","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026010913114972000_ejhf3028-bib-0016","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"2026010913114972000_ejhf3028-bib-0017","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1093\/eurheartj\/ehz239","article-title":"Prediction of individualized lifetime benefit from cholesterol lowering, blood pressure lowering, antithrombotic therapy, and smoking cessation in apparently healthy people","volume":"41","author":"Jaspers","year":"2020","journal-title":"Eur Heart J"},{"key":"2026010913114972000_ejhf3028-bib-0018","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009217","article-title":"Estimated life expectancy without recurrent cardiovascular events in patients with vascular disease: The SMART-REACH model","volume":"7","author":"Kaasenbrood","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2026010913114972000_ejhf3028-bib-0019","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1093\/eurheartj\/ehy839","article-title":"Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500\u2009000 patients with type 2 diabetes mellitus","volume":"40","author":"Berkelmans","year":"2019","journal-title":"Eur Heart J"},{"key":"2026010913114972000_ejhf3028-bib-0020","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026010913114972000_ejhf3028-bib-0021","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa1514859","article-title":"Aliskiren, enalapril, or aliskiren and enalapril in heart failure","volume":"374","author":"McMurray","year":"2016","journal-title":"N Engl J Med"},{"key":"2026010913114972000_ejhf3028-bib-0022","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/eurjhf\/hfp175","article-title":"Heart failure registry: A valuable tool for improving the management of patients with heart failure","volume":"12","author":"Jonsson","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"2026010913114972000_ejhf3028-bib-0023","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/eurjhf\/hft045","article-title":"Asian Sudden Cardiac Death in Heart Failure (ASIAN-HF) registry","volume":"15","author":"Lam","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026010913114972000_ejhf3028-bib-0024","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026010913114972000_ejhf3028-bib-0025","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jclinepi.2022.01.011","article-title":"Population median imputation was noninferior to complex approaches for imputing missing values in cardiovascular prediction models in clinical practice","volume":"145","author":"Berkelmans","year":"2022","journal-title":"J Clin Epidemiol"},{"key":"2026010913114972000_ejhf3028-bib-0026","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1161\/CIRCULATIONAHA.106.672402","article-title":"Use and misuse of the receiver operating characteristic curve in risk prediction","volume":"115","author":"Cook","year":"2007","journal-title":"Circulation"},{"key":"2026010913114972000_ejhf3028-bib-0027","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/EDE.0b013e3181c30fb2","article-title":"Assessing the performance of prediction models: A framework for traditional and novel measures","volume":"21","author":"Steyerberg","year":"2010","journal-title":"Epidemiology"},{"key":"2026010913114972000_ejhf3028-bib-0028","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1177\/2047487319846715","article-title":"Risk prediction tools in cardiovascular disease prevention: A report from the ESC Prevention of CVD Programme led by the European Association of Preventive Cardiology (EAPC) in collaboration with the Acute Cardiovascular Care Association (ACCA) and the Association of Cardiovascular Nursing and Allied Professions (ACNAP)","volume":"26","author":"Rossello","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"2026010913114972000_ejhf3028-bib-0029","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jclinepi.2007.04.018","article-title":"Updating methods improved the performance of a clinical prediction model in new patients","volume":"61","author":"Janssen","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"2026010913114972000_ejhf3028-bib-0030","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","article-title":"SCORE2 risk prediction algorithms: New models to estimate 10-year risk of cardiovascular disease in Europe","volume":"42","author":"SCORE2 Working Group and ESC Cardiovascular Risk Collaboration","year":"2021","journal-title":"Eur Heart J"},{"key":"2026010913114972000_ejhf3028-bib-0031","volume-title":"SwedeHF 2019","author":"Vasko"},{"key":"2026010913114972000_ejhf3028-bib-0032","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMc1509753","article-title":"Estimating the long-term treatment benefits of sacubitril-valsartan","volume":"373","author":"Claggett","year":"2015","journal-title":"N Engl J Med"},{"key":"2026010913114972000_ejhf3028-bib-0033","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1093\/eurheartj\/ehac056","article-title":"Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: The updated SMART2 algorithm","volume":"43","author":"Hageman","year":"2022","journal-title":"Eur Heart J"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/25\/11\/1962\/65556258\/eurjhf_25_11_1962.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/25\/11\/1962\/65556258\/eurjhf_25_11_1962.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:14:54Z","timestamp":1767982494000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/25\/11\/1962\/8342917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,18]]},"references-count":33,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,9,18]]},"published-print":{"date-parts":[[2023,11,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.3028","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11]]},"published":{"date-parts":[[2023,9,18]]},"assertion":[{"value":"2023-04-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}